Pre-clinical assessment of monoclonal antibodies and other promising vaccines/agents
Active Awarded Last action
- Contract number
- 75N91019F00135
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $16,481,250
Award facts
- Opportunity
-
- N02CO7240681 Solicitation number
- Contract value 100% obligated
- $16,481,250.00 Current and potential, with all options
- Completion date 82% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $5,243,488 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $3,759,526 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $3,653,114 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $3,796,914 | |
| Original award | $28,208 |
About this award
This is a Cost Plus Fixed Fee contract awarded by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to Leidos Biomedical Research Inc. for the pre-clinical assessment of monoclonal antibodies and other promising vaccines/agents. The potential value of the contract is $16,481,250.00 and the completion date is May 22, 2028. Leidos Biomedical Research Inc. is a subsidiary of Leidos Holdings, Inc. that provides a range of research, development, and production services to federal agencies. This contract does not have a set-aside designation. The University of Pittsburgh has been awarded a subcontract under this contract to perform activities related to TB barcode analysis and preparation of single cell suspensions for RNA sequencing to support the research efforts.
Quick answers
Who was awarded contract 75N91019F00135?
75N91019F00135 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2019.
How much is contract 75N91019F00135 worth?
The government has obligated $16,481,250 on 75N91019F00135.
Which agency awarded contract 75N91019F00135?
National Cancer Institute (National Institutes of Health) awarded 75N91019F00135, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91019F00135 an order under another contract?
Yes. 75N91019F00135 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91019F00135 competed?
The extent of competition for 75N91019F00135 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award